Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun;64(6):1201-1212.
doi: 10.1007/s00125-021-05402-w. Epub 2021 Feb 16.

Pharmacogenetics of novel glucose-lowering drugs

Affiliations
Review

Pharmacogenetics of novel glucose-lowering drugs

Wolfgang Rathmann et al. Diabetologia. 2021 Jun.

Abstract

The aim of this work was to review studies in which genetic variants were assessed with respect to metabolic response to treatment with novel glucose-lowering drugs: dipeptidyl peptidase-4 inhibitors (DPP-4i), glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i). In total, 22 studies were retrieved from the literature (MEDLINE). Variants of the GLP-1 receptor gene (GLP1R) were associated with a smaller reduction in HbA1c in response to DPP-4i. Variants of a number of other genes (KCNQ1, KCNJ11, CTRB1/2, PRKD1, CDKAL1, IL6 promoter region, TCF7L2, DPP4, PNPLA3) have also been related to DPP-4i response, although replication studies are lacking. The GLP1R gene was also reported to play a role in the response to GLP-1 RA, with larger weight reductions being reported in carriers of GLP1R variant alleles. There were variants of a few other genes (CNR1, TCF7L2, SORCS1) described to be related to GLP-1 RA. For SGLT2i, studies have focused on genes affecting renal glucose reabsorption (e.g. SLC5A2) but no relationship between SLC5A2 variants and response to empagliflozin has been found. The relevance of the included studies is limited due to small genetic effects, low sample sizes, limited statistical power, inadequate statistics (lack of gene-drug interactions), inadequate accounting for confounders and effects modifiers, and a lack of replication studies. Most studies have been based on candidate genes. Genome-wide association studies, in that respect, may be a more promising approach to providing novel insights. However, the identification of distinct subgroups of type 2 diabetes might also be necessary before pharmacogenetic studies can be successfully used for a stratified prescription of novel glucose-lowering drugs.

Keywords: Dipeptidyl peptidase-4 inhibitors; Glucagon-like peptide-1 receptor agonists; Pharmacogenetics; Precision medicine; Review; Sodium–glucose cotransporter 2 inhibitors; Type 2 diabetes.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Pearson ER. Diabetes: Is there a future for pharmacogenomics guided treatment? Clin Pharmacol Ther. 2019;106(2):329–337. doi: 10.1002/cpt.1484. - DOI - PMC - PubMed
    1. Zhou K, Yee SW, Seiser EL, et al. Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. Nat Genet. 2016;48(9):1055–1059. doi: 10.1038/ng.3632. - DOI - PMC - PubMed
    1. Rathmann W, Strassburger K, Bongaerts B, et al. A variant of the glucose transporter gene SLC2A2 modifies the glycaemic response to metformin therapy in recently diagnosed type 2 diabetes. Diabetologia. 2019;62(2):286–291. doi: 10.1007/s00125-018-4759-z. - DOI - PubMed
    1. Nasykhova YA, Tonyan ZN, Mikhailova AA, Danilova MM, Glotov AS. Pharmacogenetics of type 2 diabetes - progress and prospects. Int J Mol Sci. 2020;21(18):6842. doi: 10.3390/ijms21186842. - DOI - PMC - PubMed
    1. Heo CU, Choi CI (2019) Current progress in pharmacogenetics of second-Line antidiabetic medications: Towards precision medicine for type 2 diabetes. J Clin Med 8(3):393. 10.3390/jcm8030393 - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources